Gliadel + Avastin + Temodar
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma Multiforme
Conditions
Glioblastoma Multiforme, Gliosarcoma
Trial Timeline
Apr 1, 2011 → Jun 16, 2014
NCT ID
NCT01186406About Gliadel + Avastin + Temodar
Gliadel + Avastin + Temodar is a phase 2 stage product being developed by Eisai for Glioblastoma Multiforme. The current trial status is terminated. This product is registered under clinical trial identifier NCT01186406. Target conditions include Glioblastoma Multiforme, Gliosarcoma.
What happened to similar drugs?
1 of 18 similar drugs in Glioblastoma Multiforme were approved
Approved (1) Terminated (1) Active (16)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01186406 | Phase 2 | Terminated |
Competing Products
20 competing products in Glioblastoma Multiforme